Return to consolidated profitability for the fiscal year ending March 2020
First written in FY2018. 6 of 14 entries say "Worsened", first in FY2020-Q1. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024AchievedAnnual report
「Net profit attributable to owners of the parent turned profitable, primarily because the company applied tax-effect accounting and recognized deferred tax assets for deductible temporary differences. It recorded net profit attributable to owners of the parent of ¥186.694 million, compared with a net loss attributable to owners of the parent of ¥289.731 million in the same period of the previous year.」
The company achieved its target of a consolidated net profit from the fiscal year ending March 2024 onward, recording full-year net profit attributable to owners of the parent of ¥186.694 million. - FY2024-Q3AdvancedAnnual report
「Ordinary profit and quarterly net profit attributable to owners of the parent both turned profitable, as the company recorded foreign exchange gains and gains on the reversal of allowance for doubtful accounts from the previous fiscal year, while the impact of equity-method investment losses at an associate, which had materially affected earnings in the previous fiscal year, was limited. Ordinary profit was ¥25.790 million, compared with an ordinary loss of ¥67.637 million in the same period of the previous year, and quarterly net profit attributable to owners of the parent was ¥20.588 million, compared with a quarterly net loss attributable to owners of the parent of ¥76.430 million.」
For the nine months ended the third quarter, the company recorded ordinary profit of ¥25.790 million and quarterly net profit attributable to owners of the parent of ¥20.588 million, returning to profitability from losses in the same period of the previous year. This represented progress toward the target of achieving a consolidated net profit from the fiscal year ending March 2024 onward, but the disclosure does not state that the full-year target was achieved. - FY2023AchievedAnnual report
「Revenue was ¥794.621 million, up 22.7% year on year, and operating income was ¥58.373 million (operating loss of ¥122.219 million in the same period of the previous year), achieving the targeted return to operating profitability.」
The company achieved its target of a consolidated operating profit in the fiscal year ending March 2023, recording an operating profit of ¥58.373 million. However, it has not yet achieved its target of a consolidated net profit from the fiscal year ending March 2024 onward. - FY2023-Q3ReframedAnnual report
「In the fiscal year ending March 2023, the company is focusing on the development, manufacture, and sale of in-vitro diagnostic drugs and raw materials for in-vitro diagnostic drugs, while pursuing a global strategy using social media, and is working toward achieving a consolidated operating profit. From the fiscal year ending March 2024 onward, it also aims to achieve a consolidated net profit.」
The previous target of achieving a consolidated net profit was restructured into a phased set of targets: achieving a consolidated operating profit in the fiscal year ending March 2023, followed by achieving a consolidated net profit from the fiscal year ending March 2024 onward. - FY2023-Q2Losses narrowed, but consolidated profitability was not achievedAnnual report
「As a result, revenue was ¥293.166 million, up 15.4% year on year, and the operating loss improved significantly to ¥54.561 million (operating loss of ¥136.520 million in the same period of the previous year).」
The group's operating loss narrowed substantially from the same period of the previous year, but it posted an ordinary loss of ¥129.668 million and a net loss attributable to owners of the parent of ¥136.168 million, and therefore did not achieve consolidated profitability. - FY2021-Q3WorsenedAnnual report
「However, the testing, genetically modified silkworm, and cosmetics-related businesses have not yet reached a level of sales sufficient to generate a profit.」
The company stated that the testing, genetically modified silkworm, and cosmetics-related businesses, 3 businesses in total, had not yet reached profitable levels, despite the policy of achieving consolidated and stable profitability. - FY2021-Q1WorsenedAnnual report
「The net loss attributable to owners of the parent was ¥129.074 million, compared with a net loss attributable to owners of the parent of ¥124.603 million in the same period of the previous year.」
Despite the policy of achieving consolidated and stable profitability, the net loss attributable to owners of the parent widened year on year in the first quarter. - FY2020WorsenedAnnual report
「The net loss attributable to owners of the parent was ¥668.125 million, compared with a net loss attributable to owners of the parent of ¥167.319 million in the same period of the previous year.」
Despite the policy of achieving consolidated profitability in the fiscal year ending March 2020, the net loss attributable to owners of the parent widened to ¥668.125 million. - FY2020-Q3WorsenedAnnual report
「As a result, the net loss attributable to owners of the parent was ¥337.364 million, compared with a net loss attributable to owners of the parent of ¥76.060 million in the same period of the previous year.」
The net loss attributable to owners of the parent widened from ¥76.060 million in the same period of the previous year to ¥337.364 million, and earnings deteriorated despite the policy of achieving stable profitability. - FY2020-Q2WorsenedAnnual report
「As a result, the net loss attributable to owners of the parent was ¥254.584 million, compared with a net loss attributable to owners of the parent of ¥45.510 million in the same period of the previous year.」
The consolidated net loss widened from ¥45.510 million in the same period of the previous year to ¥254.584 million, and earnings deteriorated during the six months ended the second quarter despite the policy of achieving stable profitability. - FY2020-Q1WorsenedAnnual report
「As a result, the net loss attributable to owners of the parent was ¥124.603 million, compared with a net loss attributable to owners of the parent of ¥44.717 million in the same period of the previous year.」
The consolidated net loss widened from ¥44.717 million in the same period of the previous year to ¥124.603 million. Although the loss widened during the quarter despite the policy of achieving stable profitability, the results for this quarter alone do not indicate whether the full-year target will be achieved. - FY2019RestatedAnnual report
「Our group is a drug-discovery biotechnology venture focused on developing pharmaceuticals. Although research and development expenses arise ahead of revenue, we aim to establish a management structure that can maintain stable profitability by selling original products developed through our technologies and providing services in Japan and overseas.」
The company has reaffirmed its goal of maintaining stable profitability through product and service sales, based on a business structure in which research and development expenses are incurred ahead of revenue. - FY2019-Q3AdvancedAnnual report
「In terms of operating profit by segment for the nine months ended the third quarter, the company recorded profits in segments other than the genetically modified silkworm business.」
The diagnostics and reagents, testing, and cosmetics-related segments, excluding the genetically modified silkworm business, recorded profits. Although the mix of businesses generating profits has improved, the group as a whole continues to post an operating loss, so this does not indicate that consolidated profitability was achieved in the fiscal year ending March 2020. - FY2018First statedAnnual report
「Our group will support research and development in the genetically modified silkworm business with profits generated by the diagnostics and reagents, testing, and cosmetics-related businesses, and aims to achieve profitability on a consolidated basis in the fiscal year ending March 2020.」
The company has disclosed for the first time a goal of achieving consolidated profitability in the fiscal year ending March 2020 by generating profits from its diagnostics and reagents, testing, and cosmetics-related businesses and using those profits to support research and development in the genetically modified silkworm business.